-
1
-
-
0035899289
-
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
-
1 Yusuf, S, Zhao, F, Mehta, SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001), 494–502.
-
(2001)
N Engl J Med
, vol.345
, pp. 494-502
-
-
Yusuf, S.1
Zhao, F.2
Mehta, S.R.3
-
2
-
-
70149101223
-
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
-
2 Wallentin, L, Becker, RC, Budaj, A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
-
(2009)
N Engl J Med
, vol.361
, pp. 1045-1057
-
-
Wallentin, L.1
Becker, R.C.2
Budaj, A.3
-
3
-
-
36148983750
-
Prasugrel versus clopidogrel in patients with acute coronary syndromes
-
3 Wiviott, SD, Braunwald, E, McCabe, CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
-
(2007)
N Engl J Med
, vol.357
, pp. 2001-2015
-
-
Wiviott, S.D.1
Braunwald, E.2
McCabe, C.H.3
-
4
-
-
84929462814
-
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
-
4 Navarese, EP, Andreotti, F, Schulze, V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ, 350, 2015, h1618.
-
(2015)
BMJ
, vol.350
, pp. h1618
-
-
Navarese, E.P.1
Andreotti, F.2
Schulze, V.3
-
5
-
-
84913619061
-
2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
-
5 Windecker, S, Kolh, P, Alfonso, F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 (2014), 2541–2619.
-
(2014)
Eur Heart J
, vol.35
, pp. 2541-2619
-
-
Windecker, S.1
Kolh, P.2
Alfonso, F.3
-
6
-
-
84994777362
-
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
-
6 Levine, GN, Bates, ER, Bittl, JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68 (2016), 1082–1115.
-
(2016)
J Am Coll Cardiol
, vol.68
, pp. 1082-1115
-
-
Levine, G.N.1
Bates, E.R.2
Bittl, J.A.3
-
7
-
-
84918772240
-
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
-
7 Mauri, L, Kereiakes, DJ, Yeh, RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
-
(2014)
N Engl J Med
, vol.371
, pp. 2155-2166
-
-
Mauri, L.1
Kereiakes, D.J.2
Yeh, R.W.3
-
8
-
-
84964963457
-
Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention
-
8 Yeh, RW, Secemsky, EA, Kereiakes, DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315 (2016), 1735–1749.
-
(2016)
JAMA
, vol.315
, pp. 1735-1749
-
-
Yeh, R.W.1
Secemsky, E.A.2
Kereiakes, D.J.3
-
9
-
-
84916894797
-
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial
-
9 Pilgrim, T, Heg, D, Roffi, M, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet 384 (2014), 2111–2122.
-
(2014)
Lancet
, vol.384
, pp. 2111-2122
-
-
Pilgrim, T.1
Heg, D.2
Roffi, M.3
-
10
-
-
84865334791
-
Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial
-
10 Raber, L, Kelbaek, H, Ostojic, M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 308 (2012), 777–787.
-
(2012)
JAMA
, vol.308
, pp. 777-787
-
-
Raber, L.1
Kelbaek, H.2
Ostojic, M.3
-
11
-
-
84856452781
-
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study
-
11 Gwon, HC, Hahn, JY, Park, KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125 (2012), 505–513.
-
(2012)
Circulation
, vol.125
, pp. 505-513
-
-
Gwon, H.C.1
Hahn, J.Y.2
Park, K.W.3
-
12
-
-
84890373385
-
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial
-
12 Feres, F, Costa, RA, Abizaid, A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310 (2013), 2510–2522.
-
(2013)
JAMA
, vol.310
, pp. 2510-2522
-
-
Feres, F.1
Costa, R.A.2
Abizaid, A.3
-
13
-
-
84860135329
-
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial
-
13 Valgimigli, M, Campo, G, Monti, M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125 (2012), 2015–2026.
-
(2012)
Circulation
, vol.125
, pp. 2015-2026
-
-
Valgimigli, M.1
Campo, G.2
Monti, M.3
-
14
-
-
84867050148
-
A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
-
14 Kim, BK, Hong, MK, Shin, DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 60 (2012), 1340–1348.
-
(2012)
J Am Coll Cardiol
, vol.60
, pp. 1340-1348
-
-
Kim, B.K.1
Hong, M.K.2
Shin, D.H.3
-
15
-
-
84918810121
-
Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial
-
15 Colombo, A, Chieffo, A, Frasheri, A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 64 (2014), 2086–2097.
-
(2014)
J Am Coll Cardiol
, vol.64
, pp. 2086-2097
-
-
Colombo, A.1
Chieffo, A.2
Frasheri, A.3
-
16
-
-
84923356619
-
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates
-
16 Valgimigli, M, Patialiakas, A, Thury, A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 65 (2015), 805–815.
-
(2015)
J Am Coll Cardiol
, vol.65
, pp. 805-815
-
-
Valgimigli, M.1
Patialiakas, A.2
Thury, A.3
-
17
-
-
84949293093
-
Relation between hospital length of stay and quality of care in patients with acute coronary syndromes (from the American Heart Association's Get With the Guidelines—Coronary Artery Disease Data Set)
-
17 Tickoo, S, Bhardwaj, A, Fonarow, GC, Liang, L, Bhatt, DL, Cannon, CP, Relation between hospital length of stay and quality of care in patients with acute coronary syndromes (from the American Heart Association's Get With the Guidelines—Coronary Artery Disease Data Set). Am J Cardiol 117 (2016), 201–205.
-
(2016)
Am J Cardiol
, vol.117
, pp. 201-205
-
-
Tickoo, S.1
Bhardwaj, A.2
Fonarow, G.C.3
Liang, L.4
Bhatt, D.L.5
Cannon, C.P.6
-
18
-
-
84964370865
-
Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS
-
18 Baber, U, Mehran, R, Giustino, G, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol 67 (2016), 2224–2234.
-
(2016)
J Am Coll Cardiol
, vol.67
, pp. 2224-2234
-
-
Baber, U.1
Mehran, R.2
Giustino, G.3
-
20
-
-
84944363874
-
Evaluating the yield of medical tests
-
20 Harrell, FE Jr, Califf, RM, Pryor, DB, Lee, KL, Rosati, RA, Evaluating the yield of medical tests. JAMA 247 (1982), 2543–2546.
-
(1982)
JAMA
, vol.247
, pp. 2543-2546
-
-
Harrell, F.E.1
Califf, R.M.2
Pryor, D.B.3
Lee, K.L.4
Rosati, R.A.5
-
21
-
-
84893053141
-
Assessing discriminative ability of risk models in clustered data
-
21 van Klaveren, D, Steyerberg, EW, Perel, P, Vergouwe, Y, Assessing discriminative ability of risk models in clustered data. BMC Med Res Methodol, 14, 2014, 5.
-
(2014)
BMC Med Res Methodol
, vol.14
, pp. 5
-
-
van Klaveren, D.1
Steyerberg, E.W.2
Perel, P.3
Vergouwe, Y.4
-
22
-
-
84920572286
-
Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach
-
22 Kang, L, Chen, W, Petrick, NA, Gallas, BD, Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med 34 (2015), 685–703.
-
(2015)
Stat Med
, vol.34
, pp. 685-703
-
-
Kang, L.1
Chen, W.2
Petrick, N.A.3
Gallas, B.D.4
-
23
-
-
38849091997
-
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond
-
discussion 207–12.
-
23 Pencina, MJ, D'Agostino, RB Sr, D'Agostino, RB Jr, Vasan, RS, Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27 (2008), 157–172 discussion 207–12.
-
(2008)
Stat Med
, vol.27
, pp. 157-172
-
-
Pencina, M.J.1
D'Agostino, R.B.2
D'Agostino, R.B.3
Vasan, R.S.4
-
24
-
-
84937548548
-
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration
-
24 Moons, KG, Altman, DG, Reitsma, JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 162 (2015), W1–73.
-
(2015)
Ann Intern Med
, vol.162
, pp. W1-73
-
-
Moons, K.G.1
Altman, D.G.2
Reitsma, J.B.3
-
25
-
-
84867738043
-
The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day
-
25 Angiolillo, DJ, The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs 72 (2012), 2087–2116.
-
(2012)
Drugs
, vol.72
, pp. 2087-2116
-
-
Angiolillo, D.J.1
-
26
-
-
84877975639
-
Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status
-
26 Amin, AP, Bachuwar, A, Reid, KJ, et al. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol 61 (2013), 2130–2138.
-
(2013)
J Am Coll Cardiol
, vol.61
, pp. 2130-2138
-
-
Amin, A.P.1
Bachuwar, A.2
Reid, K.J.3
-
27
-
-
84940050465
-
Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention
-
27 Genereux, P, Giustino, G, Witzenbichler, B, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol 66 (2015), 1036–1045.
-
(2015)
J Am Coll Cardiol
, vol.66
, pp. 1036-1045
-
-
Genereux, P.1
Giustino, G.2
Witzenbichler, B.3
-
28
-
-
65549123030
-
Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score
-
28 Subherwal, S, Bach, RG, Chen, AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. Circulation 119 (2009), 1873–1882.
-
(2009)
Circulation
, vol.119
, pp. 1873-1882
-
-
Subherwal, S.1
Bach, R.G.2
Chen, A.Y.3
-
29
-
-
84979994198
-
Atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction
-
29 Bohula, EA, Bonaca, MP, Braunwald, E, et al. Atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction. Circulation 134 (2016), 304–313.
-
(2016)
Circulation
, vol.134
, pp. 304-313
-
-
Bohula, E.A.1
Bonaca, M.P.2
Braunwald, E.3
-
30
-
-
0141455899
-
Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials
-
30 Gurm, HS, Bhatt, DL, Lincoff, AM, et al. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. Heart 89 (2003), 1200–1204.
-
(2003)
Heart
, vol.89
, pp. 1200-1204
-
-
Gurm, H.S.1
Bhatt, D.L.2
Lincoff, A.M.3
-
31
-
-
84930144998
-
Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey
-
31 Valgimigli, M, Costa, F, Byrne, R, Haude, M, Baumbach, A, Windecker, S, Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention 11 (2015), 68–74.
-
(2015)
EuroIntervention
, vol.11
, pp. 68-74
-
-
Valgimigli, M.1
Costa, F.2
Byrne, R.3
Haude, M.4
Baumbach, A.5
Windecker, S.6
-
32
-
-
84975896253
-
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
-
32 Hijazi, Z, Oldgren, J, Lindback, J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 387 (2016), 2302–2311.
-
(2016)
Lancet
, vol.387
, pp. 2302-2311
-
-
Hijazi, Z.1
Oldgren, J.2
Lindback, J.3
|